Home › Glioblastoma › Massachusetts
Glioblastoma clinical trials in Massachusetts
28 studies for Glioblastoma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07326566A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Massachusetts General Hospital - Neurology, Boston
- Dana-Farber Cancer Institute - Oncology Department, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06914128Anti-GD2 ADC M3554 in Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06641908A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT03970447Implantable Microdevice In Primary Brain Tumors
- Brigham and Women's Hospital, Boston
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT04135807Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06810544SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Targeted Pediatric High-Grade Glioma Therapy
- Dana-Farber Cancer Institute, Boston
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Serial MRI Scans During Radiation Therapy
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04188535Study of Olutasidenib and Temozolomide in HGG
- Susan Chi, Boston
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT02977780Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jul 17, 2026 · NCT07225621CARv3-TEAM-E T Cells in Glioblastoma
- Massachusetts General Hospital Cancer Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT05660369DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Dana-Farber Cancer Institute, Boston
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253G-CSF After Chemo-radiation in Patients With Glioblastoma
- Massachusetts General Hospital, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT06649851SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT05941507Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
- Brigham and Women's Hospital, Boston
- Dana-Farber Brigham Cancer Center, Milford Hospital, Milford
- Dana-Farber Brigham Cancer Center, South Shore Hospital, South Weymouth
RecruitingPhase 2
Ages 65 and older · All sexes · Updated Sep 18, 2025 · NCT06835803A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 11, 2025 · NCT06552260The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- Massachusetts General Hospital, Boston
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Feb 28, 2024 · NCT06283927The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- Massachusetts General Hospital, Boston
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Feb 22, 2024 · NCT06118723The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
- Massachusetts General Hospital, Boston
RecruitingObservational study
Up to age 90 · All sexes · Updated Feb 22, 2024 · NCT06273176The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- Massachusetts General Hospital, Boston
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Nov 27, 2023 · NCT06146725The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- Massachusetts General Hospital, Boston
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Nov 27, 2023 · NCT06146738From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.